Table 3.
Antiproliferative effects of pyran-fused diterpenoids against human breast cancer cells.a
| Compounds | IC50 (μM) | |||
|---|---|---|---|---|
| MCF-7 | MDA-MB-231 | MDA-MB-468 | MCF-7/ADR | |
| 1 | 4.4 ± 1.4 | 28.0 ± 1.4 | 5.3 ± 1.4 | 34.8 ± 2.5 |
| Adriamycin | 0.67 ± 0.45 | 2.3 ± 0.22 | 0.65 ± 0.26 | >10b |
| 2 | 2.1 ± 0.35 | 2.5 ± 0.25 | 3.9 ± 2.2 | 9.0 ± 0.42 |
| 4 | 3.9 ± 0.17 | 7.8 ± 1.9 | 4.6 ± 0.18 | 12.7 ± 0.61 |
| 8 | 2.4 ± 1.5 | 2.2 ± 0.39 | 3.0 ± 0.67 | 3.8 ± 1.2 |
| 9 | 2.4 ± 1.9 | 3.7 ± 0.28 | 5.8 ± 1.9 | 6.8 ± 3.5 |
| 11 | 3.5 ± 2.2 | 6.1 ± 2.4 | 5.4 ± 0.98 | 4.7 ± 3.2 |
| 12 | 0.44 ± 0.27 | 0.54 ± 0.14 | 0.52 ± 0.18 | 1.6 ± 0.72 |
| 13 | 2.2 ± 1.3 | 1.8 ± 0.22 | 2.6 ± 0.08 | 4.4 ± 0.90 |
| 14 | 5.8 ± 3.8 | 8.2 ± 0.57 | 7.0 ± 1.0 | 10.3 ± 1.7 |
| 17 | 4.3 ± 1.8 | 7.1 ± 0.22 | 4.9 ± 0.85 | 4.3 ± 2.4 |
| 18 | 2.1 ± 0.98 | 3.3 ± 0.23 | 4.4 ± 1.5 | 3.2 ± 0.54 |
| 19 | 2.3 ± 1.0 | 3.3 ± 1.8 | 3.0 ± 1.0 | 3.1 ± 1.1 |
| 20 | 6.8 ± 3.4 | 7.2 ± 1.3 | 7.3 ± 0.23 | 8.7 ± 0.27 |
| 21 | 2.1 ± 1.1 | 3.2 ± 0.24 | 2.7 ± 0.14 | 4.5 ± 1.5 |
| 22 | 5.2 ± 2.9 | 5.9 ± 2.0 | 6.0 ± 0.29 | 5.3 ± 1.3 |
| 24 | 2.3 ± 1.4 | 2.9 ± 0.54 | 2.8 ± 0.42 | 3.8 ± 0.47 |
| 26 | 7.8 ± 3.2 | 7.6 ± 0.4 | 6.6 ± 0.77 | 8.6 ± 0.70 |
| 28 | 2.4 ± 0.78 | 2.5 ± 0.77 | 3.3 ± 0.58 | 2.9 ± 0.32 |
| 29 | 1.9 ± 0.97 | 3.3 ± 1.01 | 2.2 ± 0.68 | 3.2 ± 0.89 |
a
Breast cancer cell lines: MCF-7 (ER-positive), MDA-MB-231 and MDA-MB-468 (ER-negative and triple-negative, highly aggressive), MCF-7/ADR (adriamycin-resistant, adriamycin a.k.a. doxorubicin). Software: MasterPlex ReaderFit 2010, MiraiBio, Inc. Values are the mean ± SE of three independent experiments.
b
If a specific compound is given a value >10, it indicates that a specific IC50 cannot be calculated from the data points collected, meaning “no effect”.